M. Thuresson

First name

M.

Last name

Thuresson

Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., et al. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189

View

Rapsomaniki, E., Thuresson, M., Yang, E., Blin, P., Hunt, P., Chung, S. C., et al. (2016). Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. http://doi.org/10.1093/ehjqcco/qcw004

View

Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., et al. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo. Circulation. http://doi.org/10.1161/circulationaha.117.029190

View

Cavender, M. A., Norhammar, A., Birkeland, K. I., Jorgensen, M. E., Wilding, J. P., Khunti, K., et al. (2018). SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. http://doi.org/10.1016/j.jacc.2018.01.085

View

Heerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., et al. (2020). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. http://doi.org/10.1016/s2213-8587(19)30384-5

View